AREV

EURONEXT:AREV

AREV Life Sciences Global Corp.

  • Stock

Last Close

0.09

23/07 20:00

Market Cap

2.13M

Beta: 2.94

PE Ratio

−11.93

PFCF: −13.88

Preview

Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page

Subscribe NowHelp
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
net income
-34.02K
-
-75.22K
121.15%
-84.16K
11.88%
-251.66K
199.04%
-1.02M
305.29%
-8.43M
726.21%
-3.19M
62.11%
-1.05M
67.15%
-990.31K
5.58%
-1.44M
45.82%
depreciation and amortization
255
-
255
0%
356
39.61%
7.20K
1,923.03%
51.58K
616.25%
52.47K
1.72%
65.56K
24.95%
148.65K
126.74%
146.45K
1.48%
125.59K
14.24%
deferred income tax
144.44K
-
6.69M
4,528.68%
93.44K
98.60%
280.00K
199.65%
-808.63K
388.80%
33.99K
104.20%
stock based compensation
35K
-
197K
462.86%
602.67K
205.93%
1.06M
76.06%
105.96K
90.01%
455.41K
329.80%
144.19K
68.34%
change in working capital
5.12K
-
25.75K
403.05%
35.22K
36.76%
90.10K
155.84%
154.13K
71.07%
-202.98K
231.69%
620.10K
405.50%
423.75K
31.66%
-369.96K
187.31%
850.35K
329.85%
accounts receivables
475
-
-6.42K
-
-27.86K
333.75%
-33.92K
-
-4.60K
86.43%
-2.54K
44.81%
75.29K
3,063.01%
inventory
-22.88K
-
-18.99K
17.01%
33.92K
-
-4.63K
113.65%
-19.97K
331.48%
-75.29K
276.96%
accounts payables
152.61K
-
-215.13K
240.96%
361.25K
267.92%
178.16K
50.68%
148.01K
16.93%
555.52K
275.34%
other working capital
4.64K
-
25.75K
454.50%
119.41K
-
48.37K
59.49%
12.15K
74.88%
258.85K
2,030.09%
254.82K
1.55%
-495.46K
294.43%
294.83K
159.51%
other non cash items
45.07K
-
8.11K
-
24.66K
204.04%
36.31K
47.27%
1.24M
3,311.62%
67.00K
94.59%
97.12K
44.97%
5.59K
94.25%
net cash provided by operating activities
-28.64K
-
-4.15K
85.51%
-48.58K
1,070.67%
-111.25K
128.99%
-448.13K
302.82%
-1.25M
179.52%
-113.76K
90.92%
-23.52K
79.33%
-1.47M
6,150.76%
-284.39K
80.65%
investments in property plant and equipment
-3.20K
-
-4.55K
42.25%
-113.03K
2,383.06%
-50K
55.76%
-215.06K
330.12%
-456.14K
112.10%
-12.04K
97.36%
-81.81K
579.61%
acquisitions net
28.52K
-
20K
-
60.21K
201.06%
purchases of investments
32.65K
-
sales maturities of investments
20K
-
other investing activites
-406.24K
-
-52.65K
-
net cash used for investing activites
-3.20K
-
-4.55K
42.25%
-113.03K
2,383.06%
-427.71K
278.41%
-215.06K
49.72%
-436.14K
102.80%
48.17K
111.05%
-81.81K
269.82%
debt repayment
-68.38K
-
-100K
-
-52.65K
47.35%
-53.58K
1.77%
-5.43K
89.87%
common stock issued
255K
-
1.18M
361.57%
250.00K
-
450K
80.00%
665K
47.78%
202K
69.62%
common stock repurchased
dividends paid
other financing activites
51.80K
-
53.22K
2.72%
316.98K
495.64%
630K
98.75%
200K
68.25%
330.25K
65.13%
670.99K
103.18%
11.35K
98.31%
net cash used provided by financing activities
51.80K
-
308.22K
494.95%
1.43M
362.53%
630K
55.81%
350.00K
44.44%
727.60K
107.88%
1.28M
76.25%
207.93K
83.79%
effect of forex changes on cash
132
-
122
7.58%
35
-
52
48.57%
net change in cash
-28.64K
-
-4.15K
85.51%
22
100.53%
192.42K
874,518.18%
864.44K
349.26%
-1.05M
221.49%
21.31K
102.03%
267.94K
1,157.54%
-139.31K
151.99%
-158.22K
13.57%
cash at beginning of period
34.49K
-
5.85K
83.04%
1.70K
70.95%
1.72K
1.29%
194.14K
11,180.48%
1.06M
445.27%
8.37K
99.21%
29.68K
254.44%
297.63K
902.75%
158.31K
46.81%
cash at end of period
5.85K
-
1.70K
70.95%
1.72K
1.29%
194.14K
11,180.48%
1.06M
445.27%
8.37K
99.21%
29.68K
254.44%
297.63K
902.75%
158.31K
46.81%
94
99.94%
operating cash flow
-28.64K
-
-4.15K
85.51%
-48.58K
1,070.67%
-111.25K
128.99%
-448.13K
302.82%
-1.25M
179.52%
-113.76K
90.92%
-23.52K
79.33%
-1.47M
6,150.76%
-284.39K
80.65%
capital expenditure
-3.20K
-
-4.55K
42.25%
-113.03K
2,383.06%
-50K
55.76%
-215.06K
330.12%
-456.14K
112.10%
-12.04K
97.36%
-81.81K
579.61%
free cash flow
-28.64K
-
-4.15K
85.51%
-51.78K
1,147.78%
-115.80K
123.63%
-561.16K
384.59%
-1.30M
132.13%
-328.82K
74.76%
-479.65K
45.87%
-1.48M
208.96%
-366.20K
75.29%

All numbers in (except ratios and percentages)